Prognostic and Predictive Value of p21-activated Kinase 6 Associated Support Vector Machine Classifier in Gastric Cancer Treated by 5-fluorouracil/Oxaliplatin Chemotherapy.
Prognostic and Predictive Value of p21-activated Kinase 6 Associated Support Vector Machine Classifier in Gastric Cancer Treated by 5-fluorouracil/Oxaliplatin Chemotherapy.
复制标题
p21 激活激酶 6 相关支持向量机分类器在 5-氟尿嘧啶/奥沙利铂化疗治疗胃癌中的预后和预测价值
DOI：
10.1016/j.ebiom.2017.06.028
复制
发表时间：
2017-08
期刊：
影响因子：
11.1
通讯作者：
Li G
中科院分区：
文献类型：
--
作者：
Jiang Y;Liu W;Li T;Hu Y;Chen S;Xi S;Wen Y;Huang L;Zhao L;Xiao C;Huang X;Han Z;Liu H;Qi X;Yang Y;Yu J;Cai S;Li G
确定p21活化激酶（PAK） 6是否是胃癌（GC）的预后和预测标志物，并构建一个分类器，可以识别对5-氟尿嘧啶/奥沙利铂化疗高度敏感的患者亚群。我们采用免疫组织化学方法回顾性分析了242例训练队列石蜡包埋的GC标本中PAK6、环氧化酶2、p21WAF1、Ki-67、切除修复交叉互补基因1和胸苷酸合酶的表达水平。然后，我们使用基于支持向量机（SVM）的方法开发了化疗预测分类器（化疗评分- CS-SVM分类器）。在279例患者的独立队列中进行了进一步的验证。PAK6高表达与预后不良及5-FU/奥沙利铂化疗耐药增加相关。CS-SVM分类器将II期和III期GC患者分为低CS-SVM和高CS-SVM组，化疗患者的5年无病生存期（DFS）和总生存期（OS）差异显著。此外，化疗显著延长了训练和验证组高CS-SVM患者的DFS和OS。总之，PAK6是一个独立的预后因素，增加了化疗耐药。CS-SVM分类器区分了II期和III期患者亚组，这些患者将从化疗中获益，从而便于患者咨询和个性化管理。p21活化的激酶6是一种预测性生物标志物，增加了5-FU/奥沙利铂化疗的化疗耐药。CS-SVM分类器区分了II期和III期患者亚组，这些患者将从化疗中高度受益。PAK6是一个独立的预后因素，增加了化疗耐药。化疗评分-支持向量机分类器区分了将从化疗中获益的II期和III期患者亚组。该模型可用于患者咨询和个性化治疗决策。
To determine whether p21-activated Kinase (PAK) 6 is a prognostic and predictive marker in gastric cancer (GC) and to construct a classifier that can identify a subset of patients who are highly sensitive to 5-fluorouracil/oxaliplatin chemotherapy. We retrospectively analyzed the expression levels of PAK6, cyclooxygenase 2, p21WAF1, Ki-67, excision repair cross-complementing gene 1, and thymidylate synthase in 242 paraffin-embedded GC specimens of the training cohort by immunohistochemistry. Then, we used support vector machine (SVM)–based methods to develop a predictive classifier for chemotherapy (chemotherapy score – CS-SVM classifier). Further validation was performed in an independent cohort of 279 patients. High PAK6 expression was associated with poor prognosis and increased chemoresistance to 5-FU/oxaliplatin chemotherapy. The CS-SVM classifier distinguished patients with stage II and III GC into low- and high-CS-SVM groups, with significant differences in the 5-year disease-free survival (DFS) and overall survival (OS) in chemotherapy patients. Moreover, chemotherapy significantly prolonged the DFS and OS of the high CS-SVM patients in the training and validation cohorts. In conclusion, PAK6 was an independent prognostic factor and increased chemoresistance. The CS-SVM classifier distinguished a subgroup of stage II and III patients who would highly benefit from chemotherapy, thus facilitating patient counseling and individualizing the management. p21-activated Kinase 6 was a predictive biomarker and increased chemoresistance to 5-FU/oxaliplatin chemotherapy. The CS-SVM classifier distinguished a subgroup of stage II and III patients who would highly benefit from chemotherapy. PAK6 was an independent prognostic factor and increased chemoresistance. The chemotherapy score – support vector machine classifier distinguished a subgroup of stage II and III patients who would highly benefit from chemotherapy. The model maybe useful for patient counseling and individualized treatment decision-making.
登录
查看更多内容
影响因子：
105.7
作者：
Collins, Gary S.;Reitsma, Johannes B.;Moons, Karel G. M.
通讯作者：
Moons, Karel G. M.
影响因子：
45.3
作者：
Metzger, R;Leichman, CG;Leichman, L
通讯作者：
Leichman, L
影响因子：
5.8
作者：
Lee, Valerie;Murphy, Adrian;Diaz, Luis A., Jr.
通讯作者：
Diaz, Luis A., Jr.
影响因子：
50.5
作者：
Kwon, H. -C.;Roh, M. S.;Kim, H. -J.
通讯作者：
Kim, H. -J.
影响因子：
1.8
作者：
Choi, Hosik;Yeo, Donghwa;Kim, Yongdai
通讯作者：
Kim, Yongdai